Abstract
Objectives
Lipid nanoparticles (LNPs) play a crucial role in RNA-based therapies, and their production is generally based on nanoprecipitation and coalescence of lipids around an RNA core. This study investigated crossflow micromixing to prepare LNPs across various mixing ratios and production speeds.
Methods
A range of LNPs were prepared using crossflow micromixing across production speeds of 10–500 ml/min, and their physico-chemical characteristics (size, polydispersity index (PDI), zeta potential, and mRNA encapsulation), in vitro mRNA expression and in vitro efficacy (protein expression and antibody and cytokine responses).
Key findings
Our results demonstrate the reproducible production of mRNA–LNPs with controlled critical quality attributes, including high mRNA encapsulation from the initial screening scale through to GMP-scale production, where the same mixing ratio can be adopted across all product speeds from 30 to 500 ml/min used.
Conclusions
We confirm the applicability of stainless-steel crossflow membrane micromixing for the entire spectrum of mRNA–LNP production, ranging from initial discovery volumes to GMP-production scale.
Lipid nanoparticles (LNPs) play a crucial role in RNA-based therapies, and their production is generally based on nanoprecipitation and coalescence of lipids around an RNA core. This study investigated crossflow micromixing to prepare LNPs across various mixing ratios and production speeds.
Methods
A range of LNPs were prepared using crossflow micromixing across production speeds of 10–500 ml/min, and their physico-chemical characteristics (size, polydispersity index (PDI), zeta potential, and mRNA encapsulation), in vitro mRNA expression and in vitro efficacy (protein expression and antibody and cytokine responses).
Key findings
Our results demonstrate the reproducible production of mRNA–LNPs with controlled critical quality attributes, including high mRNA encapsulation from the initial screening scale through to GMP-scale production, where the same mixing ratio can be adopted across all product speeds from 30 to 500 ml/min used.
Conclusions
We confirm the applicability of stainless-steel crossflow membrane micromixing for the entire spectrum of mRNA–LNP production, ranging from initial discovery volumes to GMP-production scale.
| Original language | English |
|---|---|
| Pages (from-to) | 1572–1583 |
| Number of pages | 12 |
| Journal | Journal of Pharmacy and Pharmacology |
| Volume | 76 |
| Issue number | 12 |
| Early online date | 9 Oct 2024 |
| DOIs | |
| Publication status | Published - 1 Dec 2024 |
Funding
Micropore Technologies Ltd. and the University of Strathclyde ‘Healthcare Nanotechnologies’ Strathclyde Centre for Doctoral Training supported this work.
Keywords
- mRNA
- lipid nanoparticles
- manufacturing
- vaccines
- micromixing
Access to Document
Fingerprint
Dive into the research topics of 'Production of mRNA lipid nanoparticles using advanced crossflow micromixing'. Together they form a unique fingerprint.Datasets
-
Data for: "Production of mRNA Lipid nanoparticles using advanced crossflow mixing"
Hussain, M. Y. H. (Creator), Eryilmaz, B. (Creator), O'Connor, L. (Creator) & Perrie, Y. (Creator), University of Strathclyde, 17 Sept 2024
DOI: 10.15129/23e3812f-01f9-41f7-9492-56c79d9f20c1
Dataset